Soligenix Q2 FY26 net loss narrows to $2 million; revenue flat at no revenue

Reuters2026/08/07 11:32

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Soligenix posted a net loss of $2 million, or ($0.12) per share, for the quarter ended June 30, 2026.
Research and development expense fell 41.18% to $1 million, due to lower costs tied to the terminated Phase 3 FLASH2 trial.
General and administrative expense was flat at $1.1 million; revenue was no revenue.
Cash totaled about $9.8 million as of June 30, 2026, providing runway into the second quarter of 2028.
HyBryte development was discontinued after the Phase 3 FLASH2 study; focus remains on SGX945 for Behçet's disease and ThermoVax, including CEPI funding efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608070730PR_NEWS_USPR_____PH21139) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Soligenix Q2 FY26 net loss narrows to $2 million; revenue flat at no revenue

You may also like

Crypto prices